INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Lantheus Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - LNTH

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [1][2]. Financial Performance - On May 7, 2025, Lantheus reported disappointing first-quarter financial results, with sales of its oncology product Pylarify decreasing year-over-year, leading to a reduction in full-year projections [4]. - Following this announcement, Lantheus's stock price dropped by $24.35, or 23.23%, closing at $80.49 per share [5]. - On August 6, 2025, the company announced second-quarter results that also missed expectations, with Pylarify sales falling by 8.3% year-over-year, prompting further reductions in growth expectations and full-year projections [6]. - The stock price fell again by $20.76, or 28.58%, closing at $51.87 per share after the second-quarter announcement [7].